Formulation

Details Formulation Formulation

2006-01-17

2006-01-17

Padmanashan, Sreeni (Department: 1616)

Drug, bio-affecting and body treating compositions

Preparations characterized by special physical form

Particulate form

C514S174000, C514S951000, C514S958000

Reexamination Certificate

active

06986904

ABSTRACT:
A new metered unit dose comprising 40 μg or less of budesonide is disclosed as well as a formulation thereof and the use thereof for the treatment of conditions in the nose.

REFERENCES:
patent: 3992534 (1976-11-01), Brattsand et al.
patent: 5509404 (1996-04-01), Lloyd et al.
patent: 6291445 (2001-09-01), Nilsson et al.
patent: 6686346 (2004-02-01), Nilsson et al.
patent: 97/01337 (1997-01-01), None
patent: 97/01341 (1997-01-01), None
Arky, Physicians' Desk Reference, pp. 2301-2302, Medical Economics Co., Montvale, NJ 1997.
Arnon et al., “Delivery of Micronizeed Budesonide Suspension by Metered . . . A” Pediatr Pulmonol 13:172-175, Jul. 1992, Dialog Infor Sers, File 155, Medline, Dialog Acc No. 07274454, Medline Accession No. 93064921. Abstract Only.
Clissold, et al., “ADIS Drug Information Services,” Drugs 2816: pp. 485-518 1984.
Clissold et al., “Budesonide A Preliminary Review of its Pharmacodynamic Properties and Therapeutic Efficacy in Asthma and Rhinitis”, Drugs 28:485-518, 1994.
Creticos, et al., “Intranasal Budesonide Aqueos Pump Spray (Rhinocort® Aqua) for the Treatment of Seasonal Allergic Rhinitis”, Allergy and Asthama Proc., pp. 285-294, vol. 19, No. 5, Sep.- Oct. 1998.
Malm et al., “Reduction of Metacholine-Induced Nasal Secretion by Treatment with a New Topical Steroid in Perennial Non-Allergic Rhinitis”, Allergy 36:209-214, 1981.
Meltzer, “Clinical and anti-inflammatory effects of intranasal budesonide aqueous pump spray in the treatment of perennial allergic rhinitis”, Anals of Allergy, Asthma & Immunology, pp. 128-134, vol. 81, Aug., 1998.
Pedersen, et al., “Budensonide Treatment of Moderate and Severe Asthma in Childrens”, J. Alergy Clin. Immunol., 95:29-33, 1995, Abstract Only.
“Rhinocort® Nasal Inhaler”, ASTRA USA, Inc., 09-081-16-0-80 (package insert, dated Jan. 1995), 2 pages.
“Rhinocort® Aqua”, AB ASTRA Södertälje, Sweden, 09-089-62-097 (package insert, Aug. 1993), 2 pages.
“Rhinocort® Consumer Product Information”, AB Astra (package insert, dated Jun., 1995), 3 pages.
“Patient Instructions About Rhinocort® Aqua” (package insert, Feb. 1993), 2 pages.
“Rhinocort® Aqua”, ASTRA Pharma Inc. (Canada) (package insert, dated Aug. 1993), 2 pages.
“Patient Instructions About Rhinocort® Turbuhaler®”, Astra Pharma Inc. (package insert, Oct. 1993), 3 pages.
“Rhinocort® Turbuhaler®”, ASTRA Pharma Inc. (Canada) (package insert, dated Aug. 1993), 3 pages.

Affiliated with

Also associated with

Rating

Formulation does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Formulation, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Formulation will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3534832